

p95/NBS1(Phospho-Ser343) Antibody

Catalog No: #11057

Package Size: #11057-1 50ul #11057-2 100ul

Orders: order@signalwayantibody.com

Support: tech@signalwayantibody.com

Description


Product Name	p95/NBS1(Phospho-Ser343) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
Applications	WB
Species Reactivity	Hu
Specificity	The antibody detects endogenous level of p95/NBS1 only when phosphorylated at serine 343.
Immunogen Type	Peptide-KLH
Immunogen Description	Peptide sequence around phosphorylation site of serine 343 (S-L-S(p)-Q-G) derived from Human p95/NBS1.
Target Name	p95/NBS1
Modification	Phospho
Other Names	NBN
Accession No.	Swiss-Prot: O60934NCBI Protein: NP_002476.2
Concentration	1.0mg/ml
Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg ²⁺ and Ca ²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.

Application Details

Predicted MW: 95kd

Western blotting: 1:500~1:1000

Images



Western blot analysis of extracts from HeLa cells untreated or treated with Hydroxyurea using p95/NBS1(Phospho-Ser343) Antibody #11057.

Background

Mutations in p95/NBS1 gene are associated with Nijmegen breakage syndrome, an autosomal recessive chromosomal instability syndrome characterized by microcephaly, growth retardation, immunodeficiency, and cancer predisposition. The encoded protein is a member of the MRE11/RAD50 double-strand break repair complex which consists of 5 proteins. This gene product is thought to be involved in DNA double-strand break repair and DNA damage-induced checkpoint activation.

Hsu HL, et al (2005) *Oncogene*; 24(31): 4956-64.

Falck J, et al. (2005) *Nature*; 434(7033): 605-11.

Buscemi G, et al. (2004) *Oncogene*; 23(46): 7691-700.

Beausoleil SA, et al. (2004) *Proc Natl Acad Sci U S A*; 101(33): 12130-5.

Published Papers

el at., Inhibition of TPL2 by interferon- α suppresses bladder cancer through activation of PDE4D. In *J Exp Clin Cancer Res*. On 2018 Nov 27 by Qiang Z, Zhou ZY et al.. PMID: 30482227, , (2018)

[PMID:30482227](#)

Rachid Drissi, Jing Wu, Yafang Hu et al., Telomere Shortening Alters the Kinetics of the DNA Damage Response after Ionizing Radiation in Human Cells, *Cancer Prevention Research*, 4(12):1973-1981 (2011)

[PMID:21930799](#)

el at., Telomere Shortening Alters the Kinetics of the DNA Damage Response After Ionizing Radiation in Human Cells. In *Cancer Prev Res (Phila)* on 2011 Dec by Rachid Drissi, Jing Wu, et al.. PMID:21930799, , (2011)

[PMID:21930799](#)

F Carrillo, SA Schneider, AMR Taylor et al., Prominent Oromandibular Dystonia and Pharyngeal Telangiectasia in Atypical Ataxia Telangiectasia. , *Cerebellum*, 8:22-27 (2009)

[PMID:18846412](#)

el at., Prominent oromandibular dystonia and pharyngeal telangiectasia in atypical ataxia telangiectasia. In *Cerebellum* on 2009 Mar by Carrillo F, Schneider SA, et al.. PMID:18846412, , (2009)

[PMID:18846412](#)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.